Navidea Biopharmaceuticals Inc EBITDA margin
Quel est le EBITDA margin de Navidea Biopharmaceuticals Inc?
Le EBITDA margin de Navidea Biopharmaceuticals Inc est -20,121.97%
Quelle est la définition de EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin des entreprises dans Health Care secteur sur NYSEMKT par rapport à Navidea Biopharmaceuticals Inc
Que fait Navidea Biopharmaceuticals Inc?
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
Entreprises avec ebitda margin similaire à Navidea Biopharmaceuticals Inc
- Liminal BioSciences a EBITDA margin de -21,060.77%
- Peregrine Gold Ltd a EBITDA margin de -20,852.75%
- Deep Yellow a EBITDA margin de -20,849.54%
- Carnaby Resources a EBITDA margin de -20,627.90%
- Aurumin a EBITDA margin de -20,483.30%
- Nikola a EBITDA margin de -20,335.82%
- Navidea Biopharmaceuticals Inc a EBITDA margin de -20,121.97%
- Ookami a EBITDA margin de -20,061.27%
- Avita Medical a EBITDA margin de -20,041.38%
- Chant West a EBITDA margin de -19,997.24%
- Kingsland Global a EBITDA margin de -19,982.54%
- Crinetics Pharmaceuticals Inc a EBITDA margin de -19,941.16%
- E2 Metals a EBITDA margin de -19,921.03%